Boston Scientific To Acquire Penumbra, Inc. for About $14.5 Billion

Boston Scientific signed a definitive agreement to acquire Penumbra, Inc. in a cash-and-stock transaction valued at about $14.5 billion on an enterprise value basis. The deal is designed to broaden Boston Scientific’s vascular and neurovascular portfolio, particularly in mechanical thrombectomy and adjacent neurovascular markets, with expected closing in 2026 subject to regulatory approvals and Penumbra shareholder approval.